anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic hepatitis C (CHC) virus infection is a global health concern that is associated with significant liver-related morbidity and mortality. Owing to the inflammatory pathway, CHC can causefatty liver, liver cirrhosis, and liver cancer and is associated with cardiometabolic diseases, such as hypertension and diabetes. Fatty liver is associated with metabolic disorders, cardiovascular diseases, diabetes, and liver cancer. Hence, the early detection of fatty liver through noninvasive screening in adults with CHC is important in primary healthcare settings. This study aimed to explore the prevalence of fatty liver and its association with metabolic syndrome amongrural adults with CHC.
METHODS: This was a series of cohort studies related to the elimination of the CHC burden around the western coastal Yunlin County, Taiwan, between August 2018 and July 2021. A cross-sectional study was conducted after hepatitis C virus RNA confirmation in a hepatitis C- endemic area. A gastrointestinal physician or radiologist assessed fatty liver by ultrasonography. Fatty liver was classified into four grades: normal, mild, moderate, and severe. Three liver enzyme biomarkers were identified. According to the Taiwan national standard, metabolic syndrome was defined based on the presence of three or more of the five abnormal biomarkers, including increased waist circumference, elevated blood pressure, elevated fasting blood glucose level, elevated triglyceride level, and low high-density lipoprotein cholesterol level.
RESULTS: A total of 256 rural adults with CHC were enrolled. The mean age of the participants was 67.5 (standard deviation = 11.8) years, with a low educational level. High prevalence of fatty liver (79%), central obesity (54.3%), elevated blood pressure (55.5%),elevated fasting blood glucose (FBG) level (44.9%), and metabolic syndrome (37.9%) were observed.The results showed that adults with CHC with moderate to severe fatty liver were significantly associated with an increased risk of increased waist circumference (P < 0.001), increased blood pressure (P < 0.001), low high-density lipoprotein cholesterol level (P < 0.05), and elevated liver enzyme biomarker levels (all P < 0.05) after adjusting for age, sex, and educational level. Furthermore, adults with CHC with moderate to severe fatty liver were significantly associated with a greater risk of metabolic syndrome (odds ratio = 2.85, 95% confidence interval = 1.66 to 4.92).
CONCLUSIONS: The findings demonstrate a high prevalence of fatty liver in rural adults with CHC, which is significantly associated with obesity, metabolic syndrome, and elevated liver biomarker levels. Clinicians and primary healthcare providers must encourage patients with CHC to receive antiviral therapy combined with weight loss management and lifestyle modification, allowing general improvements in their liver and cardiometabolic health.
Elevations of serum triglycerides in excess of 800 mg/dL have been reported in patients treated with Claravis. Marked elevations of serum triglycerides were reported in approximately 25% of patients receiving Claravis in clinical trials. In addition, approximately 15% developed a decrease in high-density lipoproteins and about 7% showed an increase in cholesterol levels. In clinical trials, the effects on triglycerides, HDL, and cholesterol were reversible upon cessation of Claravis therapy. Some patients have been able to reverse triglyceride elevation by reduction in weight, restriction of dietary fat and alcohol, and reduction in dose while continuing Claravis.5

Blood lipid determinations should be performed before Claravis is given and then at intervals until the lipid response to Claravis is established, which usually occurs within 4 weeks. Especially careful consideration must be given to risk/benefit for patients who may be at high risk during Claravis therapy (patients with diabetes, obesity, increased alcohol intake, lipid metabolism disorder or familial history of lipid metabolism disorder). If Claravis therapy is instituted, more frequent checks of serum values for lipids and/or blood sugar are recommended (see PRECAUTIONS, Laboratory Tests).

The cardiovascular consequences of hypertriglyceridemia associated with Claravis are unknown.

###  Animal Studies

In rats given 8 or 32 mg/kg/day of isotretinoin (1.3 to 5.3 times the recommended clinical dose of 1 mg/kg/day after normalization for total body surface area) for 18 months or longer, the incidences of focal calcification, fibrosis and inflammation of the myocardium, calcification of coronary, pulmonary and mesenteric arteries, and metastatic calcification of the gastric mucosa were greater than in control rats of similar age. Focal endocardial and myocardial calcifications associated with calcification of the coronary arteries were observed in two dogs after approximately 6 to 7 months of treatment with isotretinoin at a dosage of 60 to 120 mg/kg/day (30 to 60 times the recommended clinical dose of 1 mg/kg/day, respectively, after normalization for total body surface area).
All subjects in this cohort received eltrombopag (ELT) at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that were used in this cohort were from 50 to 300 mg once daily (OD) for subjects of non-East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e., Japanese, Chinese, Taiwanese, Thai and Korean) were 25 to 150 mg. Dose adjustments (if required) were done depending on each subject's platelet counts.
Preparation of an extract from Petasites hybridus (I), which is practically free of pyrrolizidine alkaloid compounds and their N-oxide derivatives, by continuous extraction.  Also claimed is the use of (I).  Preferably extract is practically free of pyrrolizidine alkaloids and/or their N-oxide. Additional plant extracts may include valerian, passion flower, or balm extract. Extraction is continuous (see Figure 1). Pyrrolizidine alkaloids are removed using an ion-exchange material (preferably a cationic exchange medium based on an acidic polystyrene resin in the H<+> form). An alcoholic solvent is used for extraction.
PROTOCOL OUTLINE: This is a randomized, placebo-controlled study. Patients are stratified according to gender and by position of the lesion (periorbital vs nonperiorbital).

All patients receive oral prednisone daily for 3 weeks. Patients are then randomized to receive either placebo or leuprolide IM every 3 weeks, while continuing oral prednisone. Tumors are assessed at 1, 3, and 6 weeks. If the tumor is not responding, the leuprolide will be administered every 2 weeks. Tumors are reassessed at 3 and 6 months, at which point the treatment is stopped. Responding patients are observed every 3 weeks for 3 months. If the tumor begins to grow again, leuprolide may be administered for another 3 months. Patients whose tumors grow rapidly during treatment may crossover to the alternate therapy, repeat the leuprolide or prednisone therapy, or undergo surgical excision.
Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression, and coma have occurred, but were rare [ see Warnings and Precautions (5.1, 5.2, 5.4, 5.6 )].

Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.

For additional information about overdosage treatment contact a poison control center (1-800-222-1222).
1. A pharmaceutical composition comprising an antidepressive amount of 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, one of the enantiomers thereof or one of acid addition salts in combination with sertraline or one of pharmaceutically acceptable salts thereof. 2. A pharmaceutical composition in accordance with Claim 1 comprising the (+)-enantiomer of 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole (pramipexole), or one of acid addition salts thereof. 3. A pharmaceutical composition in accordance with Claim 1 comprising the (-)-enantiomer of 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, or one pharmaceutically acceptable acid salts thereof. 4. A pharmaceutical composition in accordance with any of Claims 1-3 comprising 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole dihydrochloride, first of all, 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole dihydrochloride monohydrate thereof. 5. A pharmaceutical composition in accordance with Claim 1 comprising of 0.05-10 mg of 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, one of the enantiomers thereof or one of acid addition salts thereof, pramipexole or pramipexole dihydrochloride monohydrate. 6. A pharmaceutical composition in accordance with Claim 1 comprising of 0.088-1.5 mg of 2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, one of the enantiomers thereof or one of acid addition salts thereof, pramipexole or pramipexole dihydrochloride monohydrate. 7. A pharmaceutical composition in accordance with Claim 6 comprising 0.088-1.1 mg of pramipexole, or between 0.125 and 1.5 mg of pramipexole dihydrochloride monohydrate. 8. A pharmaceutical composition in accordance with any of Claims 1-7 comprising between 25 and 200 mg of sertraline. 9. A pharmaceutical composition in accordance with Claim 8 comprising 50 mg of sertraline. 10. The use of compound of any of preceding Claims for treatment of depressions and depression conditions. 11. The use of compound of any of preceding Claims for preparation of medicine for treatment of depressions and depression conditions. 12. A method for treating depressions in patients, suffering from one of such diseases, characterized in that the combination of active substances in accordance with any of preceding Claims is used. 13. A method of Claim 12, characterized in that the active substances in the form of separate compounds are administered in series in accordance with determined temporary scheme.
Neurocristopathies such as CHARGE syndrome result from aberrant neural crest development. A large proportion of CHARGE cases are attributed to pathogenic variants in the gene encoding CHD7, chromodomain helicase DNA binding protein 7, which remodels chromatin. While the role for CHD7 in neural crest development is well documented, how this factor is specifically up-regulated in neural crest cells is not understood. Here, we use epigenomic profiling of chick and human neural crest to identify a cohort of enhancers regulating Chd7 expression in neural crest cells and other tissues. We functionally validate upstream transcription factor binding at candidate enhancers, revealing novel epistatic relationships between neural crest master regulators and Chd7, showing tissue-specific regulation of a globally acting chromatin remodeller. Furthermore, we find conserved enhancer features in human embryonic epigenomic data and validate the activity of the human equivalent CHD7 enhancers in the chick embryo. Our findings embed Chd7 in the neural crest gene regulatory network and offer potentially clinically relevant elements for interpreting CHARGE syndrome cases without causative allocation.
The intervention arm will get the usual post-discharge call from their practice, typically within 2 business days of discharge. In addition, they will be enrolled in the 30-day automated texting program, wherein they will receive check-in messages on a tapering schedule; they will be free to opt out at any time. They can also message into the platform at any time. Any needs identified through the platform will be escalated to their primary care practice, and they will receive a follow-up phone call from practice staff to address their needs.
Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
Fungal infections, although not very contagious, affect 300 million people worldwide, with immunocompromised individuals most affected. Candidiasis, cryptococcosis, aspergillosis, and pneumocystosis are major fungal infections. Cryptococcal meningitis is caused by opportunistic fungal pathogens Cryptococcus neoformans (Cne) and Cryptococcus gattii (Cga). Approximately 223,100 human patients are affected by cryptococcosis globally, with 180,000 deaths annually. Cne and Cga initially affect the lungs and, in severe conditions, the brain, leading to meningitis. The present invention screened 98,441 compounds and found 91 compounds with novel anti-Cryptococcus neoformans activity with IC 50  less than 10 uM. These compounds represent novel antifungals with the potential to treat cryptococcosis. Thus, compositions and methods for treating a fungal infection (e.g., cryptococcosis) are described herein.
Twelve to fifteen pediatric patients complaining of pain from each of the four primary language groups treated at Mbingo Baptist Hospital (Grammar English, Pidgin English, French, and Fulfulde) will be enrolled in the study. Each patient enrolled will trial the Faces Pain Scale - Revised (FPS-R) in his or her native tongue, before receiving standard analgesic treatment as ordered by the provider caring for the patient. One to two hours post analgesia, the patient will be reassessed and the FPS-R will be repeated. After completion of the second FPS-R, an audio-recorded cognitive interview will be performed by trained study personnel. These recordings will be transcribed into English and analyzed on a question-by-question basis to evaluate for themes pertaining to comprehension and understanding, ease of use, and reliability, within the different language groups. Enrollment in the study does not alter the routine pain management offered or received by patients. Rather, the FPS-R will be utilized on patients who are complaining of pain and who will be allocated to receive analgesia regardless of study enrollment.
PURPOSE:To provide an analgesic containing chlorphenesin carbamate and an acidic non-steroidal anti-inflammatory agent as active components, having excellent synergistic analgesic and muscle relaxing effects, weak acute toxicity and high safety and effective to myospasm dolorosa, etc. CONSTITUTION:The objective analgesic contains chlorphenesin carbamate and an acidic non-steroidal anti-inflammatory agent as active components. The acid non-steroidal anti-inflammatory agent is e.g. salicylic acid derivative such as sodium salicylate, pyrazolone derivative such as phenylbutazone, etc., especially preferably ibuprofen. The amount of the active component is 0.1-10pts. wt., preferably 0.5-5pts.wt. per 1pt.wt. of chlorphenesin carbamate. It may be further compounded with a hypnotic sedative, an antihistaminic agent, etc., and supplied in the form of a drug for oral administration, e.g. tablet, capsule, etc.
This open-label community demonstration project draws from parent study TIARAS (NCT05192434), a multi-component behavioral intervention designed to reduce HIV acquisition risk among women who inject drugs (WWID). Participants are prescribed PrEP prior to enrollment based on consultation with their medical provider. They then simultaneously enroll in TIARAS and this observational study. Over six months, we will use data extracted from participant's electronic medical records to (1) describe CAB-LA and daily oral PrEP uptake among WWID and (2) assess for differences in adherence and persistence among WWID prescribed CAB-LA versus daily oral PrEP. All quantitative analyses will control for random group assignment in the TIARAS trial (NCT05192434). To understand uptake (primary outcome), we will purposively sample 20 WWID who were prescribed CAB and 20 prescribed daily oral PrEP. Participants will complete a semi-structured interview designed to explore their decision to initiate PrEP and the product-related attributes that influenced their decision, accounting for previous PrEP experience or use of long-acting injectable medications (e.g., birth control or MOUD), and examining how structural factors, like homelessness or medical mistrust influence decision-making. To understand persistence and adherence, at endline (six-months) we will purposively recruit 10 women who initiated CAB-LA who remained actively engaged in care and 10 who did not. We will also purposively recruit 10 women who initiated daily oral PrEP who remained actively engaged in care and 10 who did not. All participants will complete a semi-structured interview that explores facilitators and barriers to adherence and persistence (secondary outcomes). We will focus on strategies to increase engagement in care. Because previous research highlights the important influence of seasons of risk on PrEP outcomes (i.e., women are less interested in PrEP during periods of low perceived HIV risk such as during drug abstinence), we will examine how individual and structural factors influence PrEP persistence. Finally, should we find that \>10% of the sample switches or discontinues a PrEP formulation over time, we will recruit a subset (n=15) to understand their decision-making process about switching.
The device for applying medicinal preparation in the form of powdered lyophilizate (3) to eyes of patients, comprises an applicator (1) with a holder (10) for receiving a container (2) containing the medicinal preparation, an adapter (12) communicating with the holder, where the adapter is placed in the surrounding of an eye socket of the patient with its side turned away from the holder and the medicinal preparation to be applied is detached from the container, and a compressed air-source, which is connected with the applicator over an air inlet pipe. The device for applying medicinal preparation in the form of powdered lyophilizate (3) to eyes of patients, comprises an applicator (1) with a holder (10) for receiving a container (2) containing the medicinal preparation, an adapter (12) communicating with the holder, where the adapter is placed in the surrounding of an eye socket of the patient with its side turned away from the holder and the medicinal preparation to be applied is detached from the container, and a compressed air-source, which is connected with the applicator over an air inlet pipe. The container contains a single dose of the medicinal preparation and is openable in the position incorporated in the holder. The medicinal preparation is conveyed from the container placed in the holder in the direction of the adapter under the use of gravity. The applicator comprises a downpipe, which connects the holder with the adapter and in which the medicinal preparation is enterable from the container incorporated in the holder. The downpipe is vertically aligned, where the upperside of the holder and the underside of the adapter are connected to the downpipe. The adapter is coaxially aligned to the downpipe. The air inlet pipe flows into a collection chamber within the applicator, for medicinal preparation removed from the container, and guides a discharge pipe from the collection chamber to the adapter. A compressed air bottle is provided as the compressed air-source. The holder comprises a hole for conveying the medicinal preparation removed from the container. The holder is equipped with positioning aids for accurate positioning of the container over the hole. The container is formed as a blister with a cup receiving the medicinal preparation, where the opening of the cup is covered by a peelable sealing foil. The sealing foil is fastened on a sealing edge of the blister over an adhesive layer and an adhesion-mediated coating is provided on the adhesive layer in the region of the opening of the cup. The sealing foil is applied twice in the region of the opening of the cup and comprises a flag-like projection serving as a gripping- or information-element above the blister. The opening of the eyelid is effected by the ends of the adapter, which turned away from the holder, at a position attached to the surrounding of the eye socket. The powdered lyophilizate of the medicinal preparation comprises spheroidal lyophilizate of same size with a diameter of individual particle of 100-300 mu m.
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the revised Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences and will be revised based on patient feedback in Phase 1.
BACKGROUND: Identification and characterization of circulating tumor markers, designated as "liquid biopsies," have greatly impacted the care of cancer patients. Although more recently referring to circulating tumor DNA (ctDNA), the term liquid biopsy initially was coined to refer to any blood-borne biomarker related to malignancy, including circulating tumor cells (CTCs) in blood. In this manuscript, we review the specific state of the art of CTCs in breast cancer.
CONTENT: Liquid biopsies might play a clinical role across the entire spectrum of breast cancer, from risk assessment, prevention, screening, and treatment. CTC counts have been shown to carry clear, independent prognostic information in the latter situation. However, the clinical utility of CTCs in breast cancer remains to be determined. Nonetheless, in addition to CTC enumeration, analyses of CTCs provide tumor molecular information representing the entire, often-heterogeneous disease, relatively noninvasively and longitudinally. Technological advances have allowed the interrogation of CTC-derived information, providing renewed hope for a clinical role in disease monitoring and precision oncology.
SUMMARY: This narrative review examines CTCs, their clinical validity, and current prospects of clinical utility in breast cancer with the goal of improving patient outcomes.
In Germany ovarian cancer belongs to the most frequently forms of cancer in the female population. The prognosis for women with a platin refractory ovarian cancer is very bad. The median survival time amounts for less a year. Especially in this palliative situation therapies regarding efficacy as well as quality of life are needed. in Germany Topotecan is approved since 1996 for patients after previous treatment with platin, the rare non-hematological side-effects making it interesting for a palliative therapy. Since best results in a chemo-therapeutical treatment are commonly obtained with the combination of two or more cytostatic agents this study tests a Topotecan Monotherapy and two Topotecan combinations. Both combination agents show efficacy alone against solid cancer using from Topotecan different mechanism resulting in different main side effects. Total survival, remission rates, time ti progression and quality of life are the main criteria investigated.